Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002986328 | SCV003704012 | uncertain significance | Inborn genetic diseases | 2021-04-09 | criteria provided, single submitter | clinical testing | The c.1166T>C (p.I389T) alteration is located in exon 5 (coding exon 5) of the TTI2 gene. This alteration results from a T to C substitution at nucleotide position 1166, causing the isoleucine (I) at amino acid position 389 to be replaced by a threonine (T). The p.I389T alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |